Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Trading Up 0.4% – Should You Buy?

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) shares were up 0.4% during mid-day trading on Tuesday . The stock traded as high as $24.13 and last traded at $24.03. Approximately 4,000 shares changed hands during mid-day trading, an increase of 92% from the average daily volume of 2,082 shares. The stock had previously closed at $23.94.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

The firm has a 50-day moving average price of $24.56 and a 200-day moving average price of $25.18. The stock has a market cap of $4.17 million, a PE ratio of 24.31 and a beta of 0.40.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC boosted its holdings in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent quarter.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.